Oral In-Situ Nanoplatform with Balanced Hydrophobic-Hydrophilic Property for Transport Across Gastrointestinal Mucosa

Transport of oral nanocarriers across the GI epithelium necessitates transport across hydrophilic mucus layer and the hydrophobic epithelium. Based on hydrophobic-hydrophilic balance, Curcumin-Lipomer (lipid-polymer hybrid nanoparticles) comprising hydrophobic stearic acid and hydrophilic Gantrez™ A...

Full description

Saved in:
Bibliographic Details
Published inAAPS PharmSciTech Vol. 25; no. 5; p. 113
Main Authors Attar, Esha S., Jayakumar, S., Devarajan, Padma V.
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 15.05.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Transport of oral nanocarriers across the GI epithelium necessitates transport across hydrophilic mucus layer and the hydrophobic epithelium. Based on hydrophobic-hydrophilic balance, Curcumin-Lipomer (lipid-polymer hybrid nanoparticles) comprising hydrophobic stearic acid and hydrophilic Gantrez™ AN 119 (Gantrez) were developed, by a radical in-situ approach, to successfully traverse both barriers. A monophasic preconcentrate (Cur-Pre) comprising Cur (Curcumin), stearic acid, Gantrez and stabilizers, prepared by simple solution, was added to an aqueous phase to instantaneously generate Curcumin-Lipomer (Cur-Lipo) of nanosize and high entrapment efficiency (EE). Cur-Lipo size and EE was optimized by Box-Behnken Design. Cur-Lipomers of varying hydrophobic-hydrophilic property obtained by varying the stearic acid: Gantrez ratio exhibited size in the range 200–400 nm, EE > 95% and spherical morphology as seen in the TEM. A decrease in contact angle and in mucus interaction, evident with increase in Gantrez concentration, indicated an inverse corelation with hydrophilicity, while a linear corelation was observed for mucopenetration and hydrophilicity. Cur-SLN (solid lipid nanoparticles) which served as the hydrophobic reference revealed contact angle > 90°, maximum interaction with mucus and minimal mucopenetration. The ex-vivo permeation study through chicken ileum, revealed maximum permeation with Cur-Lipo1 and comparable and significantly lower permeation of Cur-Lipo1-D and Cur-SLN proposing the importance of balancing the hydrophobic-hydrophilic property of the nanoparticles. A 1.78-fold enhancement in flux of hydrophobic Cur-SLN, with no significant change in permeation of the hydrophilic Cur-Lipomers ( p  > 0.05) following stripping off the mucosal layer was observed. This reiterated the significance of hydrophobic-hydrophilic balance as a promising strategy to design nanoformulations with superior permeation across the GI barrier. Graphical Abstract
AbstractList Transport of oral nanocarriers across the GI epithelium necessitates transport across hydrophilic mucus layer and the hydrophobic epithelium. Based on hydrophobic-hydrophilic balance, Curcumin-Lipomer (lipid-polymer hybrid nanoparticles) comprising hydrophobic stearic acid and hydrophilic Gantrez™ AN 119 (Gantrez) were developed, by a radical in-situ approach, to successfully traverse both barriers. A monophasic preconcentrate (Cur-Pre) comprising Cur (Curcumin), stearic acid, Gantrez and stabilizers, prepared by simple solution, was added to an aqueous phase to instantaneously generate Curcumin-Lipomer (Cur-Lipo) of nanosize and high entrapment efficiency (EE). Cur-Lipo size and EE was optimized by Box-Behnken Design. Cur-Lipomers of varying hydrophobic-hydrophilic property obtained by varying the stearic acid: Gantrez ratio exhibited size in the range 200-400 nm, EE > 95% and spherical morphology as seen in the TEM. A decrease in contact angle and in mucus interaction, evident with increase in Gantrez concentration, indicated an inverse corelation with hydrophilicity, while a linear corelation was observed for mucopenetration and hydrophilicity. Cur-SLN (solid lipid nanoparticles) which served as the hydrophobic reference revealed contact angle > 90°, maximum interaction with mucus and minimal mucopenetration. The ex-vivo permeation study through chicken ileum, revealed maximum permeation with Cur-Lipo1 and comparable and significantly lower permeation of Cur-Lipo1-D and Cur-SLN proposing the importance of balancing the hydrophobic-hydrophilic property of the nanoparticles. A 1.78-fold enhancement in flux of hydrophobic Cur-SLN, with no significant change in permeation of the hydrophilic Cur-Lipomers (p > 0.05) following stripping off the mucosal layer was observed. This reiterated the significance of hydrophobic-hydrophilic balance as a promising strategy to design nanoformulations with superior permeation across the GI barrier.Transport of oral nanocarriers across the GI epithelium necessitates transport across hydrophilic mucus layer and the hydrophobic epithelium. Based on hydrophobic-hydrophilic balance, Curcumin-Lipomer (lipid-polymer hybrid nanoparticles) comprising hydrophobic stearic acid and hydrophilic Gantrez™ AN 119 (Gantrez) were developed, by a radical in-situ approach, to successfully traverse both barriers. A monophasic preconcentrate (Cur-Pre) comprising Cur (Curcumin), stearic acid, Gantrez and stabilizers, prepared by simple solution, was added to an aqueous phase to instantaneously generate Curcumin-Lipomer (Cur-Lipo) of nanosize and high entrapment efficiency (EE). Cur-Lipo size and EE was optimized by Box-Behnken Design. Cur-Lipomers of varying hydrophobic-hydrophilic property obtained by varying the stearic acid: Gantrez ratio exhibited size in the range 200-400 nm, EE > 95% and spherical morphology as seen in the TEM. A decrease in contact angle and in mucus interaction, evident with increase in Gantrez concentration, indicated an inverse corelation with hydrophilicity, while a linear corelation was observed for mucopenetration and hydrophilicity. Cur-SLN (solid lipid nanoparticles) which served as the hydrophobic reference revealed contact angle > 90°, maximum interaction with mucus and minimal mucopenetration. The ex-vivo permeation study through chicken ileum, revealed maximum permeation with Cur-Lipo1 and comparable and significantly lower permeation of Cur-Lipo1-D and Cur-SLN proposing the importance of balancing the hydrophobic-hydrophilic property of the nanoparticles. A 1.78-fold enhancement in flux of hydrophobic Cur-SLN, with no significant change in permeation of the hydrophilic Cur-Lipomers (p > 0.05) following stripping off the mucosal layer was observed. This reiterated the significance of hydrophobic-hydrophilic balance as a promising strategy to design nanoformulations with superior permeation across the GI barrier.
Transport of oral nanocarriers across the GI epithelium necessitates transport across hydrophilic mucus layer and the hydrophobic epithelium. Based on hydrophobic-hydrophilic balance, Curcumin-Lipomer (lipid-polymer hybrid nanoparticles) comprising hydrophobic stearic acid and hydrophilic Gantrez™ AN 119 (Gantrez) were developed, by a radical in-situ approach, to successfully traverse both barriers. A monophasic preconcentrate (Cur-Pre) comprising Cur (Curcumin), stearic acid, Gantrez and stabilizers, prepared by simple solution, was added to an aqueous phase to instantaneously generate Curcumin-Lipomer (Cur-Lipo) of nanosize and high entrapment efficiency (EE). Cur-Lipo size and EE was optimized by Box-Behnken Design. Cur-Lipomers of varying hydrophobic-hydrophilic property obtained by varying the stearic acid: Gantrez ratio exhibited size in the range 200–400 nm, EE > 95% and spherical morphology as seen in the TEM. A decrease in contact angle and in mucus interaction, evident with increase in Gantrez concentration, indicated an inverse corelation with hydrophilicity, while a linear corelation was observed for mucopenetration and hydrophilicity. Cur-SLN (solid lipid nanoparticles) which served as the hydrophobic reference revealed contact angle > 90°, maximum interaction with mucus and minimal mucopenetration. The ex-vivo permeation study through chicken ileum, revealed maximum permeation with Cur-Lipo1 and comparable and significantly lower permeation of Cur-Lipo1-D and Cur-SLN proposing the importance of balancing the hydrophobic-hydrophilic property of the nanoparticles. A 1.78-fold enhancement in flux of hydrophobic Cur-SLN, with no significant change in permeation of the hydrophilic Cur-Lipomers ( p  > 0.05) following stripping off the mucosal layer was observed. This reiterated the significance of hydrophobic-hydrophilic balance as a promising strategy to design nanoformulations with superior permeation across the GI barrier. Graphical Abstract
Transport of oral nanocarriers across the GI epithelium necessitates transport across hydrophilic mucus layer and the hydrophobic epithelium. Based on hydrophobic-hydrophilic balance, Curcumin-Lipomer (lipid-polymer hybrid nanoparticles) comprising hydrophobic stearic acid and hydrophilic Gantrez™ AN 119 (Gantrez) were developed, by a radical in-situ approach, to successfully traverse both barriers. A monophasic preconcentrate (Cur-Pre) comprising Cur (Curcumin), stearic acid, Gantrez and stabilizers, prepared by simple solution, was added to an aqueous phase to instantaneously generate Curcumin-Lipomer (Cur-Lipo) of nanosize and high entrapment efficiency (EE). Cur-Lipo size and EE was optimized by Box-Behnken Design. Cur-Lipomers of varying hydrophobic-hydrophilic property obtained by varying the stearic acid: Gantrez ratio exhibited size in the range 200-400 nm, EE > 95% and spherical morphology as seen in the TEM. A decrease in contact angle and in mucus interaction, evident with increase in Gantrez concentration, indicated an inverse corelation with hydrophilicity, while a linear corelation was observed for mucopenetration and hydrophilicity. Cur-SLN (solid lipid nanoparticles) which served as the hydrophobic reference revealed contact angle > 90°, maximum interaction with mucus and minimal mucopenetration. The ex-vivo permeation study through chicken ileum, revealed maximum permeation with Cur-Lipo1 and comparable and significantly lower permeation of Cur-Lipo1-D and Cur-SLN proposing the importance of balancing the hydrophobic-hydrophilic property of the nanoparticles. A 1.78-fold enhancement in flux of hydrophobic Cur-SLN, with no significant change in permeation of the hydrophilic Cur-Lipomers (p > 0.05) following stripping off the mucosal layer was observed. This reiterated the significance of hydrophobic-hydrophilic balance as a promising strategy to design nanoformulations with superior permeation across the GI barrier.
ArticleNumber 113
Author Jayakumar, S.
Attar, Esha S.
Devarajan, Padma V.
Author_xml – sequence: 1
  givenname: Esha S.
  surname: Attar
  fullname: Attar, Esha S.
  organization: Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology Matunga (E)
– sequence: 2
  givenname: S.
  surname: Jayakumar
  fullname: Jayakumar, S.
  organization: Radiation Biology and Health Sciences Division, Modular Laboratories, Bhabha Atomic Research Centre, Homi Bhabha National Institute
– sequence: 3
  givenname: Padma V.
  orcidid: 0000-0002-5701-3107
  surname: Devarajan
  fullname: Devarajan, Padma V.
  email: pvdevarajan@gmail.com
  organization: Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology Matunga (E)
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38750336$$D View this record in MEDLINE/PubMed
BookMark eNp9kMtOAyEYhYnR2FZ9AReGpZtRBuYCy2q0NqmXRF0TYBhLM4URmJi-vWirceUCOAnn_By-Cdi3zmoATnN0kWNEL0OOccEyhIu0aNrpHhjnJUEZYwTv_9EjMAlhhRAmOSOHYERoXSJCqjEYHr3o4NxmzyYO8EFY13cits6v4YeJS3glOmGVbuDdpvGuXzppVLbTpjMKPiWlfdzAlIEvXtjQOx_hVHkXApyJEL0zNuoQjU0v3Q_KBXEMDlrRBX2yO4_A6-3Ny_Vdtnicza-ni0xhRmNWFwzLQlQNaguZE9lKQlmORNOgokZa1A1mtUztKKEK0wq3bVnVslW6LktZNeQInG_n9t69D6kDX5ugdJf-pN0QOEFlSRkpWJ2seGv9Lu51y3tv1sJveI74F26-xc0Tbv6Nm9MUOtvNH-RaN7-RH77JQLaGkK7sm_Z85QafQIT_xn4Chk-PbA
Cites_doi 10.1016/j.apsb.2022.10.020
10.1021/acsami.8b18107
10.1021/la702680x
10.1126/sciadv.1601556
10.1080/17425247.2018.1420055
10.1016/j.addr.2005.07.008
10.1002/btm2.10112
10.1023/A:1019854327540
10.1166/jnn.2014.9015
10.2217/nnm.12.129
10.1016/j.ijpharm.2020.120181
10.1002/smll.201201789
10.1016/j.carbpol.2015.10.021
10.2174/138920013804545133
10.1016/j.addr.2011.12.009
10.1016/j.addr.2017.07.015
10.1021/acsami.6b08183
10.1016/j.addr.2017.10.001
10.1021/acsnano.3c02403
10.1016/j.colsurfb.2014.07.037
10.1016/j.ejpb.2015.01.005
10.1016/j.medidd.2021.100110
10.1016/j.nano.2016.08.025
10.1016/j.ijpharm.2017.09.040
10.1038/nrd.2018.183
10.1021/la010444o
10.1016/j.cej.2021.132107
10.1016/j.jconrel.2022.07.030
10.1016/j.ejpb.2014.12.024
10.1016/j.jcis.2020.08.010
10.1038/s41467-021-21989-5
10.1016/j.jconrel.2017.12.034
10.2217/nnm.09.110
10.1016/j.ijpharm.2017.09.018
10.1016/j.addr.2017.12.006
10.1039/C3CS60436E
10.1002/adma.201201800
10.17756/jfcn.2017-046
10.1016/j.ejpb.2015.05.004
10.1016/j.ijpharm.2021.120511
10.1016/j.jddst.2022.103162
10.1038/s41467-018-05061-3
10.1016/j.aca.2007.07.011
10.1016/j.ijpharm.2015.04.073
10.1016/j.addr.2017.10.004
10.1016/j.jconrel.2020.01.006
10.1016/j.ijpharm.2012.02.042
10.1016/j.jconrel.2021.04.026
10.1016/j.addr.2018.01.001
10.1002/chem.200903335
10.1016/j.addr.2017.08.010
10.1002/9781119414018.ch5
10.22028/D291-22833
10.1002/anie.201006849
ContentType Journal Article
Copyright The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
Copyright_xml – notice: The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1208/s12249-024-02824-8
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1530-9932
ExternalDocumentID 10_1208_s12249_024_02824_8
38750336
Genre Journal Article
GroupedDBID ---
-56
-5G
-BR
-EM
-~C
.86
.VR
06C
06D
0R~
0VY
1N0
203
23M
29~
2J2
2JN
2JY
2KG
2KM
2LR
2~H
30V
406
408
40D
40E
53G
5GY
5VS
67N
6J9
6NX
875
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AAKDD
AANZL
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
ABAKF
ABDZT
ABECU
ABFGW
ABFTV
ABHLI
ABHQN
ABJNI
ABJOX
ABKCH
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABWNU
ABXPI
ACAOD
ACDTI
ACGFO
ACGFS
ACHSB
ACIPQ
ACKNC
ACMDZ
ACMJI
ACMLO
ACOKC
ACOMO
ACREN
ACSNA
ACWMK
ACZOJ
ADBBV
ADHHG
ADHIR
ADINQ
ADKNI
ADKPE
ADRFC
ADURQ
ADYFF
ADYOE
ADZKW
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AESTI
AETLH
AEVLU
AEVTX
AEXYK
AFBBN
AFLOW
AFQWF
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGMZJ
AGQEE
AGQMX
AGRTI
AGWZB
AGYKE
AHAVH
AHBYD
AHKAY
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AIMYW
AITGF
AJRNO
AJZVZ
AKMHD
AKQUC
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
AXYYD
B-.
BA0
BAWUL
BGNMA
CS3
CSCUP
DDRTE
DNIVK
DPUIP
E3Z
EBLON
EBS
EIOEI
EMOBN
ESBYG
F5P
FERAY
FFXSO
FIGPU
FNLPD
FRRFC
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
HG6
HMJXF
HRMNR
IJ-
IKXTQ
IWAJR
IXC
IXD
I~X
I~Z
J-C
J0Z
JBSCW
JZLTJ
KOV
KPH
LGEZI
LLZTM
LOTEE
M4Y
MA-
NADUK
NPVJJ
NQJWS
NU0
NXXTH
O93
O9I
O9J
OK1
P2P
PF0
PT4
QOR
QOS
R89
R9I
ROL
RPM
RPX
RSV
S16
S1Z
S27
S3A
S3B
SAP
SBL
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SZN
T13
TR2
TSG
TSV
TUC
U2A
U9L
UG4
UNUBA
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WK8
XSB
YLTOR
Z45
Z7U
Z7V
Z7W
Z7X
Z81
Z87
ZMTXR
ZOVNA
~A9
AAYZH
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c298t-7492b4a6d0f4b13bfb38910add0470ea7d297bced838c2862ff567bfce755b6d3
IEDL.DBID AGYKE
ISSN 1530-9932
IngestDate Sat Oct 26 04:07:44 EDT 2024
Thu Sep 12 20:28:21 EDT 2024
Tue Oct 29 09:07:37 EDT 2024
Wed Sep 04 01:21:03 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords transepithelial transport
lipomer
hydrophobic-hydrophilic balance
approach
mucopenetration
curcumin
in-situ approach
Language English
License 2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c298t-7492b4a6d0f4b13bfb38910add0470ea7d297bced838c2862ff567bfce755b6d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-5701-3107
PMID 38750336
PQID 3055893497
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3055893497
crossref_primary_10_1208_s12249_024_02824_8
pubmed_primary_38750336
springer_journals_10_1208_s12249_024_02824_8
PublicationCentury 2000
PublicationDate 2024-05-15
PublicationDateYYYYMMDD 2024-05-15
PublicationDate_xml – month: 05
  year: 2024
  text: 2024-05-15
  day: 15
PublicationDecade 2020
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: United States
PublicationSubtitle An Official Journal of the American Association of Pharmaceutical Scientists
PublicationTitle AAPS PharmSciTech
PublicationTitleAbbrev AAPS PharmSciTech
PublicationTitleAlternate AAPS PharmSciTech
PublicationYear 2024
Publisher Springer International Publishing
Publisher_xml – name: Springer International Publishing
References Teubl, Meindl, Eitzlmayr, Zimmer, Fröhlich, Roblegg (CR54) 2013; 9
Valamla, Thakor, Phuse, Dalvi, Kharat, Kumar (CR27) 2022; 70
Khutoryanskiy (CR21) 2018; 124
Todke, Devarajan (CR39) 2022; 349
de Sousa, Steiner, Schmutzler, Wilcox, Veldhuis, Pearson (CR49) 2015; 97
Jindal, Devarajan (CR36) 2015; 489
Takeuchi, Thongborisute, Matsui, Sugihara, Yamamoto, Kawashima (CR48) 2005; 57
Azioune, Chehimi, Miksa, Basinska, Slomkowski (CR44) 2002; 18
Ren, Wu, Zhang (CR51) 2023; 13
Leal, Smyth, Ghosh (CR12) 2017; 532
Liu, Jiang, Gan, Yu (CR17) 2021; 12
Huckaby, Lai (CR9) 2018; 124
Gao, He, Zhang, Zhang, Gao, Wang (CR20) 2021; 582
Hu, Pei, Duan, Zhu, Liu, Chen (CR33) 2021; 12
Ensign, Schneider, Suk, Cone, Hanes (CR19) 2012; 24
Svensson, Thuresson, Arnebrant (CR47) 2008; 24
Dos Santos, Carvalho, Meneguin, Sábio, Gremião, Chorilli (CR52) 2021; 334
Zhang, Cheng, Dong, Zhang, Liu, Wang (CR24) 2018; 272
Ensign, Cone, Hanes (CR8) 2012; 64
Nordgård, Draget (CR46) 2018; 124
John, Dalal, Shankarkumar, Devarajan (CR38) 2021; 600
Mo, Jiang, Di, Tai, Gu (CR6) 2014; 43
Joshi, Patwardhan, Sharma, Sandur, Devarajan (CR30) 2021; 595
Anselmo, Gokarn, Mitragotri (CR15) 2019; 18
Mittal, Patel, Jhaveri, Kay, Debs, Parrish (CR2) 2018; 15
Wu, Shan, Zhang, Huang (CR23) 2018; 124
Homayouni, Sadeghi, Varshosaz, Garekani, Nokhodchi (CR42) 2014; 122
Chater, Wilcox, Pearson (CR45) 2018; 124
Kapse, Gaikwad, Samad, Devarajan (CR37) 2012; 429
CR18
Westerhout, Bellmann, van Ee, Havenaar, Leeman, Steeg (CR34) 2017; 3
Menzel, Bernkop-Schnürch (CR11) 2018; 124
CR14
CR13
Fang, Wang, Yao, Zhang, Wu, Li (CR25) 2017; 13
Griffiths, Cattoz, Ibrahim, Anuonye (CR50) 2015; 97
Crick, Parkin (CR43) 2010; 16
Ejazi, Louisthelmy, Maisel (CR1) 2023; 17
Forier, Messiaen, Raemdonck, Deschout, Rejman, De Baets (CR26) 2013; 8
D'Souza, Devarajan (CR40) 2016; 136
Roger, Lagarce, Garcion, Benoit (CR4) 2010; 5
Bachhav, Dighe, Kotak, Devarajan (CR3) 2017; 532
Grießinger, Dünnhaupt, Cattoz, Griffiths, Oh, Igómez (CR32) 2015; 96
Schneider, Xu, Boylan, Chisholm, Tang, Schuster (CR22) 2017; 3
Hu, Yang, Wang, Wang, He, Tang (CR28) 2022; 428
Froehlich, Roblegg (CR53) 2014; 14
Shan, Zhu, Tao, Cui, Liu, Wu (CR7) 2016; 8
Behrens, Pena, Alonso, Kissel (CR35) 2002; 19
Ferreira, Bruns, Ferreira, Matos, David, Brandão (CR41) 2007; 597
Poinard, Kamaluddin, Tan, Neoh, Kah (CR31) 2019; 11
Shahbazi, Santos (CR5) 2013; 14
Yu, Xu, Tian, Su, Zheng, Yang (CR10) 2018; 9
Jahagirdar, Gupta, Kulkarni, Devarajan (CR29) 2019; 4
Macedo, Castro, Roque, Thomé, Reis, Pintado (CR16) 2020; 320
2824_CR18
2824_CR14
2824_CR13
PA Todke (2824_CR39) 2022; 349
O Svensson (2824_CR47) 2008; 24
W Shan (2824_CR7) 2016; 8
IP de Sousa (2824_CR49) 2015; 97
Y Ren (2824_CR51) 2023; 13
X Zhang (2824_CR24) 2018; 272
AA D'Souza (2824_CR40) 2016; 136
K Forier (2824_CR26) 2013; 8
CT Nordgård (2824_CR46) 2018; 124
LM Ensign (2824_CR8) 2012; 64
L Wu (2824_CR23) 2018; 124
CR Crick (2824_CR43) 2010; 16
SS Bachhav (2824_CR3) 2017; 532
AM Dos Santos (2824_CR52) 2021; 334
R Mittal (2824_CR2) 2018; 15
H Takeuchi (2824_CR48) 2005; 57
PS Jahagirdar (2824_CR29) 2019; 4
B Poinard (2824_CR31) 2019; 11
B Valamla (2824_CR27) 2022; 70
CS Schneider (2824_CR22) 2017; 3
Y Gao (2824_CR20) 2021; 582
HA Joshi (2824_CR30) 2021; 595
AS Macedo (2824_CR16) 2020; 320
AB Jindal (2824_CR36) 2015; 489
AC Anselmo (2824_CR15) 2019; 18
L Fang (2824_CR25) 2017; 13
PI Chater (2824_CR45) 2018; 124
BJ Teubl (2824_CR54) 2013; 9
VV Khutoryanskiy (2824_CR21) 2018; 124
C Liu (2824_CR17) 2021; 12
J Leal (2824_CR12) 2017; 532
E Roger (2824_CR4) 2010; 5
A Azioune (2824_CR44) 2002; 18
R John (2824_CR38) 2021; 600
R Mo (2824_CR6) 2014; 43
S Hu (2824_CR28) 2022; 428
J Grießinger (2824_CR32) 2015; 96
PC Griffiths (2824_CR50) 2015; 97
A Homayouni (2824_CR42) 2014; 122
LM Ensign (2824_CR19) 2012; 24
E Froehlich (2824_CR53) 2014; 14
C Menzel (2824_CR11) 2018; 124
SV Kapse (2824_CR37) 2012; 429
JT Huckaby (2824_CR9) 2018; 124
I Behrens (2824_CR35) 2002; 19
M-A Shahbazi (2824_CR5) 2013; 14
J Westerhout (2824_CR34) 2017; 3
S Hu (2824_CR33) 2021; 12
SA Ejazi (2824_CR1) 2023; 17
SC Ferreira (2824_CR41) 2007; 597
M Yu (2824_CR10) 2018; 9
References_xml – volume: 13
  start-page: 2544
  issue: 6
  year: 2023
  end-page: 2558
  ident: CR51
  article-title: The feasibility of oral targeted drug delivery: Gut immune to particulates?
  publication-title: Acta Pharmaceutica Sinica B
  doi: 10.1016/j.apsb.2022.10.020
  contributor:
    fullname: Zhang
– volume: 11
  start-page: 4777
  issue: 5
  year: 2019
  end-page: 4789
  ident: CR31
  article-title: Polydopamine coating enhances mucopenetration and cell uptake of nanoparticles
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.8b18107
  contributor:
    fullname: Kah
– volume: 24
  start-page: 2573
  issue: 6
  year: 2008
  end-page: 2579
  ident: CR47
  article-title: Interactions between drug delivery particles and mucin in solution and at interfaces
  publication-title: Langmuir
  doi: 10.1021/la702680x
  contributor:
    fullname: Arnebrant
– volume: 3
  start-page: e1601556
  issue: 4
  year: 2017
  ident: CR22
  article-title: Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation
  publication-title: Sci Adv
  doi: 10.1126/sciadv.1601556
  contributor:
    fullname: Schuster
– volume: 15
  start-page: 301
  issue: 3
  year: 2018
  end-page: 18
  ident: CR2
  article-title: Recent advancements in nanoparticle based drug delivery for gastrointestinal disorders
  publication-title: Expert Opin Drug Deliv.
  doi: 10.1080/17425247.2018.1420055
  contributor:
    fullname: Parrish
– volume: 57
  start-page: 1583
  issue: 11
  year: 2005
  end-page: 1594
  ident: CR48
  article-title: Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2005.07.008
  contributor:
    fullname: Kawashima
– volume: 4
  start-page: 141
  issue: 1
  year: 2019
  end-page: 151
  ident: CR29
  article-title: Polymeric curcumin nanoparticles by a facile in situ method for macrophage targeted delivery
  publication-title: Bioeng Transl Med
  doi: 10.1002/btm2.10112
  contributor:
    fullname: Devarajan
– volume: 19
  start-page: 1185
  year: 2002
  end-page: 1193
  ident: CR35
  article-title: Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport
  publication-title: Pharm Res
  doi: 10.1023/A:1019854327540
  contributor:
    fullname: Kissel
– volume: 14
  start-page: 126
  issue: 1
  year: 2014
  end-page: 136
  ident: CR53
  article-title: Mucus as barrier for drug delivery by nanoparticles
  publication-title: J Nanosci Nanotechnol
  doi: 10.1166/jnn.2014.9015
  contributor:
    fullname: Roblegg
– volume: 8
  start-page: 935
  issue: 6
  year: 2013
  end-page: 949
  ident: CR26
  article-title: Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy
  publication-title: Nanomedicine
  doi: 10.2217/nnm.12.129
  contributor:
    fullname: De Baets
– volume: 595
  start-page: 120181
  year: 2021
  ident: CR30
  article-title: Pre-clinical evaluation of an innovative oral nano-formulation of baicalein for modulation of radiation responses
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2020.120181
  contributor:
    fullname: Devarajan
– volume: 9
  start-page: 457
  issue: 3
  year: 2013
  end-page: 466
  ident: CR54
  article-title: In-vitro permeability of neutral polystyrene particles via buccal mucosa
  publication-title: Small
  doi: 10.1002/smll.201201789
  contributor:
    fullname: Roblegg
– volume: 136
  start-page: 1251
  year: 2016
  end-page: 1258
  ident: CR40
  article-title: Bioenhanced oral curcumin nanoparticles: role of carbohydrates
  publication-title: Carbohyd Polym
  doi: 10.1016/j.carbpol.2015.10.021
  contributor:
    fullname: Devarajan
– volume: 14
  start-page: 28
  issue: 1
  year: 2013
  end-page: 56
  ident: CR5
  article-title: Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication
  publication-title: Curr Drug Metab.
  doi: 10.2174/138920013804545133
  contributor:
    fullname: Santos
– volume: 64
  start-page: 557
  issue: 6
  year: 2012
  end-page: 570
  ident: CR8
  article-title: Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2011.12.009
  contributor:
    fullname: Hanes
– volume: 124
  start-page: 140
  year: 2018
  end-page: 149
  ident: CR21
  article-title: Beyond PEGylation: alternative surface-modification of nanoparticles with mucus-inert biomaterials
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2017.07.015
  contributor:
    fullname: Khutoryanskiy
– volume: 8
  start-page: 25444
  issue: 38
  year: 2016
  end-page: 25453
  ident: CR7
  article-title: Enhanced oral delivery of protein drugs using zwitterion-functionalized nanoparticles to overcome both the diffusion and absorption barriers
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.6b08183
  contributor:
    fullname: Wu
– volume: 124
  start-page: 150
  year: 2018
  end-page: 163
  ident: CR23
  article-title: Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2017.10.001
  contributor:
    fullname: Huang
– volume: 17
  start-page: 13044
  issue: 14
  year: 2023
  end-page: 13061
  ident: CR1
  article-title: Mechanisms of nanoparticle transport across intestinal tissue: an oral delivery perspective
  publication-title: ACS Nano
  doi: 10.1021/acsnano.3c02403
  contributor:
    fullname: Maisel
– volume: 122
  start-page: 591
  year: 2014
  end-page: 600
  ident: CR42
  article-title: Promising dissolution enhancement effect of soluplus on crystallized celecoxib obtained through antisolvent precipitation and high pressure homogenization techniques
  publication-title: Colloids Surf B
  doi: 10.1016/j.colsurfb.2014.07.037
  contributor:
    fullname: Nokhodchi
– volume: 96
  start-page: 464
  year: 2015
  end-page: 76
  ident: CR32
  article-title: Methods to determine the interactions of micro-and nanoparticles with mucus
  publication-title: Eur J Pharm Biopharm
  doi: 10.1016/j.ejpb.2015.01.005
  contributor:
    fullname: Igómez
– volume: 12
  start-page: 100110
  year: 2021
  ident: CR17
  article-title: Engineering nanoparticles to overcome the mucus barrier for drug delivery: Design, evaluation and state-of-the-art
  publication-title: Medicine in Drug Discovery
  doi: 10.1016/j.medidd.2021.100110
  contributor:
    fullname: Yu
– ident: CR18
– volume: 13
  start-page: 153
  issue: 1
  year: 2017
  end-page: 71
  ident: CR25
  article-title: Micro-and nano-carrier systems: The non-invasive and painless local administration strategies for disease therapy in mucosal tissues
  publication-title: Nanomedicine.
  doi: 10.1016/j.nano.2016.08.025
  contributor:
    fullname: Li
– volume: 532
  start-page: 612
  issue: 1
  year: 2017
  end-page: 622
  ident: CR3
  article-title: Rifampicin Lipid-Polymer hybrid nanoparticles (LIPOMER) for enhanced Peyer’s patch uptake
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2017.09.040
  contributor:
    fullname: Devarajan
– volume: 18
  start-page: 19
  issue: 1
  year: 2019
  end-page: 40
  ident: CR15
  article-title: Non-invasive delivery strategies for biologics
  publication-title: Nat Rev Drug Discovery
  doi: 10.1038/nrd.2018.183
  contributor:
    fullname: Mitragotri
– volume: 18
  start-page: 1150
  issue: 4
  year: 2002
  end-page: 1156
  ident: CR44
  article-title: Hydrophobic protein− polypyrrole interactions: The role of van der Waals and Lewis acid− base forces as determined by contact angle measurements
  publication-title: Langmuir
  doi: 10.1021/la010444o
  contributor:
    fullname: Slomkowski
– ident: CR14
– volume: 428
  start-page: 132107
  year: 2022
  ident: CR28
  article-title: Zwitterionic polydopamine modified nanoparticles as an efficient nanoplatform to overcome both the mucus and epithelial barriers
  publication-title: Chem Eng J
  doi: 10.1016/j.cej.2021.132107
  contributor:
    fullname: Tang
– volume: 349
  start-page: 756
  year: 2022
  end-page: 764
  ident: CR39
  article-title: In-silico approach as a tool for selection of excipients for safer amphotericin B nanoformulations
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2022.07.030
  contributor:
    fullname: Devarajan
– volume: 97
  start-page: 273
  year: 2015
  end-page: 279
  ident: CR49
  article-title: Mucus permeating carriers: formulation and characterization of highly densely charged nanoparticles
  publication-title: Eur J Pharm Biopharm
  doi: 10.1016/j.ejpb.2014.12.024
  contributor:
    fullname: Pearson
– volume: 582
  start-page: 364
  year: 2021
  end-page: 375
  ident: CR20
  article-title: Zwitterion-functionalized mesoporous silica nanoparticles for enhancing oral delivery of protein drugs by overcoming multiple gastrointestinal barriers
  publication-title: J Colloid Interface Sci
  doi: 10.1016/j.jcis.2020.08.010
  contributor:
    fullname: Wang
– volume: 12
  start-page: 1689
  issue: 1
  year: 2021
  ident: CR33
  article-title: A mussel-inspired film for adhesion to wet buccal tissue and efficient buccal drug delivery
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-21989-5
  contributor:
    fullname: Chen
– volume: 272
  start-page: 29
  year: 2018
  end-page: 38
  ident: CR24
  article-title: Design and intestinal mucus penetration mechanism of core-shell nanocomplex
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2017.12.034
  contributor:
    fullname: Wang
– volume: 5
  start-page: 287
  issue: 2
  year: 2010
  end-page: 306
  ident: CR4
  article-title: Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery
  publication-title: Nanomedicine
  doi: 10.2217/nnm.09.110
  contributor:
    fullname: Benoit
– volume: 532
  start-page: 555
  issue: 1
  year: 2017
  end-page: 572
  ident: CR12
  article-title: Physicochemical properties of mucus and their impact on transmucosal drug delivery
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2017.09.018
  contributor:
    fullname: Ghosh
– volume: 124
  start-page: 184
  year: 2018
  end-page: 192
  ident: CR45
  article-title: Efficacy and safety concerns over the use of mucus modulating agents for drug delivery using nanoscale systems
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2017.12.006
  contributor:
    fullname: Pearson
– volume: 43
  start-page: 3595
  issue: 10
  year: 2014
  end-page: 3629
  ident: CR6
  article-title: Emerging micro-and nanotechnology based synthetic approaches for insulin delivery
  publication-title: Chem Soc Rev
  doi: 10.1039/C3CS60436E
  contributor:
    fullname: Gu
– volume: 24
  start-page: 3887
  issue: 28
  year: 2012
  end-page: 3894
  ident: CR19
  article-title: Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery
  publication-title: Adv Mater
  doi: 10.1002/adma.201201800
  contributor:
    fullname: Hanes
– volume: 3
  start-page: 111
  issue: 4
  year: 2017
  end-page: 9
  ident: CR34
  article-title: Prediction of oral absorption of nanoparticles from biorelevant matrices using a combination of physiologically relevant in vitro and ex vivo models
  publication-title: J Food Chem Nanotechnol.
  doi: 10.17756/jfcn.2017-046
  contributor:
    fullname: Steeg
– volume: 97
  start-page: 218
  year: 2015
  end-page: 222
  ident: CR50
  article-title: Probing the interaction of nanoparticles with mucin for drug delivery applications using dynamic light scattering
  publication-title: Eur J Pharm Biopharm
  doi: 10.1016/j.ejpb.2015.05.004
  contributor:
    fullname: Anuonye
– volume: 600
  year: 2021
  ident: CR38
  article-title: Innovative betulin nanosuspension exhibits enhanced anticancer activity in a triple negative breast cancer cell line and Zebrafish angiogenesis model
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2021.120511
  contributor:
    fullname: Devarajan
– volume: 70
  start-page: 103162
  year: 2022
  ident: CR27
  article-title: Engineering drug delivery systems to overcome the vaginal mucosal barrier: Current understanding and research agenda of mucoadhesive formulations of vaginal delivery
  publication-title: J Drug Deliv Sci Technol
  doi: 10.1016/j.jddst.2022.103162
  contributor:
    fullname: Kumar
– volume: 9
  start-page: 2607
  issue: 1
  year: 2018
  ident: CR10
  article-title: Rapid transport of deformation-tuned nanoparticles across biological hydrogels and cellular barriers
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-05061-3
  contributor:
    fullname: Yang
– volume: 597
  start-page: 179
  issue: 2
  year: 2007
  end-page: 186
  ident: CR41
  article-title: Box-Behnken design: An alternative for the optimization of analytical methods
  publication-title: Anal Chim Acta
  doi: 10.1016/j.aca.2007.07.011
  contributor:
    fullname: Brandão
– volume: 489
  start-page: 246
  issue: 1–2
  year: 2015
  end-page: 251
  ident: CR36
  article-title: Asymmetric lipid–polymer particles (LIPOMER) by modified nanoprecipitation: role of non-solvent composition
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2015.04.073
  contributor:
    fullname: Devarajan
– ident: CR13
– volume: 124
  start-page: 164
  year: 2018
  end-page: 174
  ident: CR11
  article-title: Enzyme decorated drug carriers: targeted swords to cleave and overcome the mucus barrier
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2017.10.004
  contributor:
    fullname: Bernkop-Schnürch
– volume: 320
  start-page: 125
  year: 2020
  end-page: 141
  ident: CR16
  article-title: Novel and revisited approaches in nanoparticle systems for buccal drug delivery
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2020.01.006
  contributor:
    fullname: Pintado
– volume: 429
  start-page: 104
  issue: 1–2
  year: 2012
  end-page: 112
  ident: CR37
  article-title: Self nanoprecipitating preconcentrate of tamoxifen citrate for enhanced bioavailability
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2012.02.042
  contributor:
    fullname: Devarajan
– volume: 334
  start-page: 353
  year: 2021
  end-page: 366
  ident: CR52
  article-title: Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2021.04.026
  contributor:
    fullname: Chorilli
– volume: 124
  start-page: 175
  year: 2018
  end-page: 183
  ident: CR46
  article-title: Co association of mucus modulating agents and nanoparticles for mucosal drug delivery
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2018.01.001
  contributor:
    fullname: Draget
– volume: 16
  start-page: 3568
  issue: 12
  year: 2010
  end-page: 88
  ident: CR43
  article-title: Preparation and characterisation of super-hydrophobic surfaces
  publication-title: Chem Eur J.
  doi: 10.1002/chem.200903335
  contributor:
    fullname: Parkin
– volume: 124
  start-page: 125
  year: 2018
  end-page: 139
  ident: CR9
  article-title: PEGylation for enhancing nanoparticle diffusion in mucus
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2017.08.010
  contributor:
    fullname: Lai
– ident: 2824_CR14
  doi: 10.1002/9781119414018.ch5
– volume: 122
  start-page: 591
  year: 2014
  ident: 2824_CR42
  publication-title: Colloids Surf B
  doi: 10.1016/j.colsurfb.2014.07.037
  contributor:
    fullname: A Homayouni
– volume: 349
  start-page: 756
  year: 2022
  ident: 2824_CR39
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2022.07.030
  contributor:
    fullname: PA Todke
– volume: 595
  start-page: 120181
  year: 2021
  ident: 2824_CR30
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2020.120181
  contributor:
    fullname: HA Joshi
– volume: 429
  start-page: 104
  issue: 1–2
  year: 2012
  ident: 2824_CR37
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2012.02.042
  contributor:
    fullname: SV Kapse
– volume: 8
  start-page: 935
  issue: 6
  year: 2013
  ident: 2824_CR26
  publication-title: Nanomedicine
  doi: 10.2217/nnm.12.129
  contributor:
    fullname: K Forier
– volume: 8
  start-page: 25444
  issue: 38
  year: 2016
  ident: 2824_CR7
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.6b08183
  contributor:
    fullname: W Shan
– volume: 124
  start-page: 140
  year: 2018
  ident: 2824_CR21
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2017.07.015
  contributor:
    fullname: VV Khutoryanskiy
– volume: 320
  start-page: 125
  year: 2020
  ident: 2824_CR16
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2020.01.006
  contributor:
    fullname: AS Macedo
– volume: 9
  start-page: 2607
  issue: 1
  year: 2018
  ident: 2824_CR10
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-05061-3
  contributor:
    fullname: M Yu
– volume: 3
  start-page: e1601556
  issue: 4
  year: 2017
  ident: 2824_CR22
  publication-title: Sci Adv
  doi: 10.1126/sciadv.1601556
  contributor:
    fullname: CS Schneider
– volume: 600
  year: 2021
  ident: 2824_CR38
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2021.120511
  contributor:
    fullname: R John
– volume: 124
  start-page: 125
  year: 2018
  ident: 2824_CR9
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2017.08.010
  contributor:
    fullname: JT Huckaby
– volume: 334
  start-page: 353
  year: 2021
  ident: 2824_CR52
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2021.04.026
  contributor:
    fullname: AM Dos Santos
– volume: 5
  start-page: 287
  issue: 2
  year: 2010
  ident: 2824_CR4
  publication-title: Nanomedicine
  doi: 10.2217/nnm.09.110
  contributor:
    fullname: E Roger
– volume: 597
  start-page: 179
  issue: 2
  year: 2007
  ident: 2824_CR41
  publication-title: Anal Chim Acta
  doi: 10.1016/j.aca.2007.07.011
  contributor:
    fullname: SC Ferreira
– volume: 489
  start-page: 246
  issue: 1–2
  year: 2015
  ident: 2824_CR36
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2015.04.073
  contributor:
    fullname: AB Jindal
– volume: 136
  start-page: 1251
  year: 2016
  ident: 2824_CR40
  publication-title: Carbohyd Polym
  doi: 10.1016/j.carbpol.2015.10.021
  contributor:
    fullname: AA D'Souza
– volume: 15
  start-page: 301
  issue: 3
  year: 2018
  ident: 2824_CR2
  publication-title: Expert Opin Drug Deliv.
  doi: 10.1080/17425247.2018.1420055
  contributor:
    fullname: R Mittal
– volume: 97
  start-page: 273
  year: 2015
  ident: 2824_CR49
  publication-title: Eur J Pharm Biopharm
  doi: 10.1016/j.ejpb.2014.12.024
  contributor:
    fullname: IP de Sousa
– volume: 43
  start-page: 3595
  issue: 10
  year: 2014
  ident: 2824_CR6
  publication-title: Chem Soc Rev
  doi: 10.1039/C3CS60436E
  contributor:
    fullname: R Mo
– volume: 11
  start-page: 4777
  issue: 5
  year: 2019
  ident: 2824_CR31
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.8b18107
  contributor:
    fullname: B Poinard
– volume: 70
  start-page: 103162
  year: 2022
  ident: 2824_CR27
  publication-title: J Drug Deliv Sci Technol
  doi: 10.1016/j.jddst.2022.103162
  contributor:
    fullname: B Valamla
– ident: 2824_CR13
  doi: 10.22028/D291-22833
– volume: 582
  start-page: 364
  year: 2021
  ident: 2824_CR20
  publication-title: J Colloid Interface Sci
  doi: 10.1016/j.jcis.2020.08.010
  contributor:
    fullname: Y Gao
– volume: 4
  start-page: 141
  issue: 1
  year: 2019
  ident: 2824_CR29
  publication-title: Bioeng Transl Med
  doi: 10.1002/btm2.10112
  contributor:
    fullname: PS Jahagirdar
– volume: 64
  start-page: 557
  issue: 6
  year: 2012
  ident: 2824_CR8
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2011.12.009
  contributor:
    fullname: LM Ensign
– volume: 18
  start-page: 19
  issue: 1
  year: 2019
  ident: 2824_CR15
  publication-title: Nat Rev Drug Discovery
  doi: 10.1038/nrd.2018.183
  contributor:
    fullname: AC Anselmo
– volume: 124
  start-page: 150
  year: 2018
  ident: 2824_CR23
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2017.10.001
  contributor:
    fullname: L Wu
– volume: 96
  start-page: 464
  year: 2015
  ident: 2824_CR32
  publication-title: Eur J Pharm Biopharm
  doi: 10.1016/j.ejpb.2015.01.005
  contributor:
    fullname: J Grießinger
– volume: 24
  start-page: 3887
  issue: 28
  year: 2012
  ident: 2824_CR19
  publication-title: Adv Mater
  doi: 10.1002/adma.201201800
  contributor:
    fullname: LM Ensign
– volume: 124
  start-page: 175
  year: 2018
  ident: 2824_CR46
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2018.01.001
  contributor:
    fullname: CT Nordgård
– volume: 272
  start-page: 29
  year: 2018
  ident: 2824_CR24
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2017.12.034
  contributor:
    fullname: X Zhang
– volume: 57
  start-page: 1583
  issue: 11
  year: 2005
  ident: 2824_CR48
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2005.07.008
  contributor:
    fullname: H Takeuchi
– volume: 16
  start-page: 3568
  issue: 12
  year: 2010
  ident: 2824_CR43
  publication-title: Chem Eur J.
  doi: 10.1002/chem.200903335
  contributor:
    fullname: CR Crick
– volume: 17
  start-page: 13044
  issue: 14
  year: 2023
  ident: 2824_CR1
  publication-title: ACS Nano
  doi: 10.1021/acsnano.3c02403
  contributor:
    fullname: SA Ejazi
– volume: 12
  start-page: 1689
  issue: 1
  year: 2021
  ident: 2824_CR33
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-21989-5
  contributor:
    fullname: S Hu
– volume: 14
  start-page: 126
  issue: 1
  year: 2014
  ident: 2824_CR53
  publication-title: J Nanosci Nanotechnol
  doi: 10.1166/jnn.2014.9015
  contributor:
    fullname: E Froehlich
– volume: 532
  start-page: 555
  issue: 1
  year: 2017
  ident: 2824_CR12
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2017.09.018
  contributor:
    fullname: J Leal
– volume: 532
  start-page: 612
  issue: 1
  year: 2017
  ident: 2824_CR3
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2017.09.040
  contributor:
    fullname: SS Bachhav
– volume: 9
  start-page: 457
  issue: 3
  year: 2013
  ident: 2824_CR54
  publication-title: Small
  doi: 10.1002/smll.201201789
  contributor:
    fullname: BJ Teubl
– volume: 428
  start-page: 132107
  year: 2022
  ident: 2824_CR28
  publication-title: Chem Eng J
  doi: 10.1016/j.cej.2021.132107
  contributor:
    fullname: S Hu
– volume: 12
  start-page: 100110
  year: 2021
  ident: 2824_CR17
  publication-title: Medicine in Drug Discovery
  doi: 10.1016/j.medidd.2021.100110
  contributor:
    fullname: C Liu
– volume: 97
  start-page: 218
  year: 2015
  ident: 2824_CR50
  publication-title: Eur J Pharm Biopharm
  doi: 10.1016/j.ejpb.2015.05.004
  contributor:
    fullname: PC Griffiths
– volume: 24
  start-page: 2573
  issue: 6
  year: 2008
  ident: 2824_CR47
  publication-title: Langmuir
  doi: 10.1021/la702680x
  contributor:
    fullname: O Svensson
– volume: 3
  start-page: 111
  issue: 4
  year: 2017
  ident: 2824_CR34
  publication-title: J Food Chem Nanotechnol.
  doi: 10.17756/jfcn.2017-046
  contributor:
    fullname: J Westerhout
– volume: 13
  start-page: 153
  issue: 1
  year: 2017
  ident: 2824_CR25
  publication-title: Nanomedicine.
  doi: 10.1016/j.nano.2016.08.025
  contributor:
    fullname: L Fang
– volume: 18
  start-page: 1150
  issue: 4
  year: 2002
  ident: 2824_CR44
  publication-title: Langmuir
  doi: 10.1021/la010444o
  contributor:
    fullname: A Azioune
– volume: 124
  start-page: 184
  year: 2018
  ident: 2824_CR45
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2017.12.006
  contributor:
    fullname: PI Chater
– volume: 13
  start-page: 2544
  issue: 6
  year: 2023
  ident: 2824_CR51
  publication-title: Acta Pharmaceutica Sinica B
  doi: 10.1016/j.apsb.2022.10.020
  contributor:
    fullname: Y Ren
– volume: 14
  start-page: 28
  issue: 1
  year: 2013
  ident: 2824_CR5
  publication-title: Curr Drug Metab.
  doi: 10.2174/138920013804545133
  contributor:
    fullname: M-A Shahbazi
– volume: 19
  start-page: 1185
  year: 2002
  ident: 2824_CR35
  publication-title: Pharm Res
  doi: 10.1023/A:1019854327540
  contributor:
    fullname: I Behrens
– volume: 124
  start-page: 164
  year: 2018
  ident: 2824_CR11
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2017.10.004
  contributor:
    fullname: C Menzel
– ident: 2824_CR18
  doi: 10.1002/anie.201006849
SSID ssj0023193
Score 2.426189
Snippet Transport of oral nanocarriers across the GI epithelium necessitates transport across hydrophilic mucus layer and the hydrophobic epithelium. Based on...
SourceID proquest
crossref
pubmed
springer
SourceType Aggregation Database
Index Database
Publisher
StartPage 113
SubjectTerms Administration, Oral
Animals
Biochemistry
Biological Transport - physiology
Biomedical and Life Sciences
Biomedicine
Biotechnology
Curcumin - administration & dosage
Curcumin - chemistry
Curcumin - pharmacokinetics
Drug Carriers - chemistry
Hydrophobic and Hydrophilic Interactions
Intestinal Mucosa - metabolism
Lipids - chemistry
Nanoparticles - chemistry
Particle Size
Pharmacology/Toxicology
Pharmacy
Polymers - chemistry
Polyvinyls - chemistry
Research Article
Stearic Acids - chemistry
Title Oral In-Situ Nanoplatform with Balanced Hydrophobic-Hydrophilic Property for Transport Across Gastrointestinal Mucosa
URI https://link.springer.com/article/10.1208/s12249-024-02824-8
https://www.ncbi.nlm.nih.gov/pubmed/38750336
https://www.proquest.com/docview/3055893497
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Nb9MwFH_auguX8T0KbPIktAv1SGMnsY8d2tYNDSrRSuNk2Y4tKqakyseh_PXY-WiFipB2yyF2kvf9_N77BeCDicx4bJ1-O3caY0ppiDlTFI-58iZZqjDw08h3X-Ppgt7eR_fbOe6m2b2vSDaGugFACNin0peAOHYuBfs0gWK2Dwd-8DQawMHk-seXy02e5aSKdPMx_175tw_aCSx3iqKNr7l6CvN-YqdtMfl1XlfqXP_eBXB8zGc8g8Mu9kSTVliew57JXsDZrAWvXo_QfDuLVY7QGZptYa3XL6H-VrjFNxn-vqxq5KxyvnqQlY95kT_MRRe-SVKbFE3XaZGvfuZqqXF3vXxYajTz5_5FtUZuDdqAqqNJQyR0LcuqyD16hTM6_jXvfC-9fAWLq8v55ynuftqAdchZhRPKQ0VlnAaWqjFRVvlKaODMaECTwMgkDXni5CBlhOnQ5VPWRnGirDZJFKk4Ja9hkOWZeQNIM-3CIWtkbBklmsnI6JgTyQwlxCo-hI89G8WqxeYQPqdxdBYtnYWjs2joLNgQTntOC6dCvi4iM5PXpfCgZy5sozwZwlErApv9CGsKvfEQRj0_Rafl5X8e9vZxt7-DJ2EjEr6R8j0MqqI2xy7YqdRJJ9wnsL8IJ38AwOD6Bw
link.rule.ids 315,783,787,27938,27939,41095,41537,42164,42606,52125,52248
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwEB7BcoAL4k1ZHkZCe6EWSewk9rEgli5sl0q00t4s27FFpVVSJemh_349eXSFFiFxyyGT1zeeh2fmC8AHl7o49mF9B3eaUc55QqUwnMbSoEnWJolwGnlxkc3X_PtlejkMhTVjt_tYkuwsdceAEIlPDdaAJA0-hWKewKm4C_eQXx31ep3MDmlWUCo2jMf8Xe5PF3QrrrxVE-1czekjeDjEiGTWg_oY7rjyCZwse5Lp_ZSsbmammik5Icsb-un9U9j9rIPwWUl_bdodCdaz2l7pFmNTgpuu5DM2M1pXkPm-qKvt78psLB2ON1cbS5a4P1-3exJkyIH8nMy6tyHfdNPWFbJMBOOAj7nAnnf9DNanX1df5nT4uQK1iRQtzblMDNdZEXluYma8wYplFMxdxPPI6bxIZB7wKgQTNgl5j_dplhtvXZ6mJivYczgqq9K9BGKFDWGLdzrzgjMrdOpsJpkWjjPmjZzAx_F7q23PoaEw9wjoqB4dFdBRHTpKTOD9CIkKqo71C126atcoJCcL4RWX-QRe9FgdrsdEV5DNJjAdwVPDamz-cbNX_3f6O7g_Xy3O1fnZxY9jeJB0SpXSOH0NR229c29CgNKat50-XgP1ht_8
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7BVkJceD-Wp5FQL6zbJHYS57hAt1tKy0q0UjlZtmOrq1bJKnEOy6_HzmMLFCEhbjnEiTMez8PfzBeAtzrWYWjc_nbuNMGU0ghnTFIcZtKbZCGjwHcjHx0n81P66Sw--6mLv612HyDJrqfBszQVdneVm44NIWC7tceDMuz8C_Y5A8XsJmzR0IULI9ia7n873NskXU7FSN8s8-eRvzqka1HmNYS0dTyzuyCGKXf1Jhc7jZU76vtvbI7_80334E4flaJpp0b34YYuHsD2oqO1Xk_QyVWXVj1B22hxRXi9fgjNl8oNPijw16VtkLPX5epSWB8NI3_Mi9778kmlczRf51W5Oi_lUuH-enm5VGjhEYHKrpEbgzZ062jaSgzti9pWpee1cObIT_PIV9mLR3A62zv5MMf97xywijJmcUqzSFKR5IGhMiTSSI-RBs7ABjQNtEjzKEudhuSMMBW5TMuYOEmlUTqNY5nk5DGMirLQTwEpplygZLRIDKNEMRFrlWREME0JMTIbw7thTfmqY-3gPttxcuadnLmTM2_lzNkY3gzLzt3m8oiJKHTZ1NzTobmAjmbpGJ50-rB5HmEtBJyMYTKsLe_3f_2Xlz37t9tfw63Fxxn_fHB8-BxuR612xDiMX8DIVo1-6SIiK1_1Sv8DaMEF6g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oral+In-Situ+Nanoplatform+with+Balanced+Hydrophobic-Hydrophilic+Property+for+Transport+Across+Gastrointestinal+Mucosa&rft.jtitle=AAPS+PharmSciTech&rft.au=Attar%2C+Esha+S&rft.au=Jayakumar%2C+S&rft.au=Devarajan%2C+Padma+V&rft.date=2024-05-15&rft.issn=1530-9932&rft.eissn=1530-9932&rft.volume=25&rft.issue=5&rft.spage=113&rft_id=info:doi/10.1208%2Fs12249-024-02824-8&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1530-9932&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1530-9932&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1530-9932&client=summon